ロード中...

Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature

Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce. Methods: Patients for monotherapy with either Atezolizumab, Nivolumab or Pembrolizumab after che...

詳細記述

保存先:
書誌詳細
出版年:Front Oncol
主要な著者: Fuhrmann, Christian, Struck, Julian P., Ivanyi, Philipp, Kramer, Mario W., Hupe, Marie C., Hensen, Bennet, Fürschke, Alexander, Peters, Inga, Merseburger, Axel S., Kuczyk, Markus A., von Klot, Christoph-A. J.
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2020
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7253725/
https://ncbi.nlm.nih.gov/pubmed/32528889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00808
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!